Literature DB >> 17306503

Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeys.

Rao Zhou1, Cristin M Bruns, Ian M Bird, Joseph W Kemnitz, Theodore L Goodfriend, Daniel A Dumesic, David H Abbott.   

Abstract

PURPOSE OF THE STUDY: To determine whether pioglitazone will improve menstrual cyclicity in a fetal programming model for polycystic ovary syndrome. BASIC PROCEDURES: Eight prenatally androgenized (PA) and 5 control female rhesus monkeys of similar age, body weight and body mass index received an oral placebo daily for 6-7 months followed, after at least 90 days, by daily oral dosing with pioglitazone (3mg/kg) for an additional 6-7 months. Blood was sampled thrice weekly to monitor ovulatory function, and a variety of endocrine challenges were performed to quantify changes in ovarian, gonadotropin and glucoregulatory function. MOST IMPORTANT
FINDINGS: Pioglitazone normalized menstrual cycles in 5 out of 8 (62%) PA females (pioglitazone responsive; Pio(RESP)). Pioglitazone increased serum 17alpha-hydroxyprogesterone responses to an hCG injection in Pio(RESP) PA females, while diminishing serum progesterone, and increasing DHEA and estradiol responses to hCG in Pio(RESP) PA and all normal females. PRINCIPAL
CONCLUSIONS: Insulin resistance plays a mechanistic role in maintaining anovulation in a majority of PA female monkeys.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17306503      PMCID: PMC2705750          DOI: 10.1016/j.reprotox.2006.12.009

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  68 in total

Review 1.  Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

Authors:  D A Ehrmann; R B Barnes; R L Rosenfield
Journal:  Endocr Rev       Date:  1995-06       Impact factor: 19.871

2.  Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.

Authors:  Rachele Berria; Amalia Gastaldelli; Scott Lucidi; Renata Belfort; Eleanna De Filippis; Caraan Easton; Robert Brytzki; Kenneth Cusi; Lois Jovanovic; Ralph DeFronzo
Journal:  Clin Pharmacol Ther       Date:  2006-06-30       Impact factor: 6.875

3.  Luteal phase deficiency: abnormal gonadotropin and progesterone secretion patterns.

Authors:  M R Soules; D K Clifton; N L Cohen; W J Bremner; R A Steiner
Journal:  J Clin Endocrinol Metab       Date:  1989-10       Impact factor: 5.958

4.  Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.

Authors:  L Ibañez; J E Hall; N Potau; A Carrascosa; N Prat; A E Taylor
Journal:  J Clin Endocrinol Metab       Date:  1996-11       Impact factor: 5.958

5.  Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production.

Authors:  Donna Seto-Young; Maria Paliou; Jonathan Schlosser; Dimiter Avtanski; Alice Park; Parini Patel; Kevin Holcomb; Peter Chang; Leonid Poretsky
Journal:  J Clin Endocrinol Metab       Date:  2005-08-30       Impact factor: 5.958

Review 6.  Polycystic ovary syndrome.

Authors:  S Franks
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

Review 7.  Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.

Authors:  S Giannini; M Serio; A Galli
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

8.  Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome.

Authors:  Jessica K Wickenheisser; Velen L Nelson-DeGrave; Karen L Hendricks; Richard S Legro; Jerome F Strauss; Jan M McAllister
Journal:  J Clin Endocrinol Metab       Date:  2005-05-24       Impact factor: 5.958

9.  Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone.

Authors:  Mickey S Coffler; Ketan Patel; Michael H Dahan; Richard Y Yoo; Pamela J Malcom; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

10.  Luteinization in primates is accompanied by loss of a 43-kilodalton adenosine 3',5'-monophosphate response element-binding protein isoform.

Authors:  J P Somers; D F Benyo; L Little-Ihrig; A J Zeleznik
Journal:  Endocrinology       Date:  1995-11       Impact factor: 4.736

View more
  28 in total

1.  PPARG regulates gonadotropin-releasing hormone signaling in LbetaT2 cells in vitro and pituitary gonadotroph function in vivo in mice.

Authors:  Shweta Sharma; Prem M Sharma; Devendra S Mistry; R Jeffery Chang; Jerrold M Olefsky; Pamela L Mellon; Nicholas J G Webster
Journal:  Biol Reprod       Date:  2010-11-10       Impact factor: 4.285

Review 2.  Fetal programming of polycystic ovary syndrome.

Authors:  Esra Bahar Gur; Muammer Karadeniz; Guluzar Arzu Turan
Journal:  World J Diabetes       Date:  2015-07-10

Review 3.  Hyperandrogenic origins of polycystic ovary syndrome - implications for pathophysiology and therapy.

Authors:  David H Abbott; Daniel A Dumesic; Jon E Levine
Journal:  Expert Rev Endocrinol Metab       Date:  2019-02-15

Review 4.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

5.  Experimentally induced gestational androgen excess disrupts glucoregulation in rhesus monkey dams and their female offspring.

Authors:  David H Abbott; Cristin R Bruns; Deborah K Barnett; Andrea Dunaif; Theodore L Goodfriend; Daniel A Dumesic; Alice F Tarantal
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-08-03       Impact factor: 4.310

Review 6.  Mechanisms of intergenerational transmission of polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Luis R Hoyos; Gregorio D Chazenbalk; Rajanigandha Naik; Vasantha Padmanabhan; David H Abbott
Journal:  Reproduction       Date:  2020-01       Impact factor: 3.906

7.  Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys.

Authors:  David H Abbott; Deborah K Barnett; Jon E Levine; Vasantha Padmanabhan; Daniel A Dumesic; Steve Jacoris; Alice F Tarantal
Journal:  Biol Reprod       Date:  2008-04-02       Impact factor: 4.285

8.  Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females.

Authors:  V Padmanabhan; A Veiga-Lopez; D H Abbott; S E Recabarren; C Herkimer
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

Review 9.  Effects of prenatal androgens on rhesus monkeys: a model system to explore the organizational hypothesis in primates.

Authors:  Jan Thornton; Julia L Zehr; Michael D Loose
Journal:  Horm Behav       Date:  2009-05       Impact factor: 3.587

Review 10.  Nonhuman primate models of polycystic ovary syndrome.

Authors:  David H Abbott; Lindsey E Nicol; Jon E Levine; Ning Xu; Mark O Goodarzi; Daniel A Dumesic
Journal:  Mol Cell Endocrinol       Date:  2013-01-29       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.